Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacteroides fragilis BF839
- Development stage
- Unknown
- Lead developer
- Second Affiliated Hospital of Guangzhou Medical University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Vaginal
01
Overview
Bacteroides fragilis BF839 is a non-toxic, non-enterotoxigenic, gram-negative, obligate anaerobic bacillus originally isolated from a healthy infant in 1983. Classified as a next-generation probiotic (NGP) or live biotherapeutic product (LBP), it is widely used in China to address gut microbiota dysbiosis-related conditions such as constipation and diarrhea. Beyond its use as a probiotic, BF839 has been investigated in clinical settings for autism spectrum disorder (ASD), autoimmune diseases, and refractory epilepsy. Its mechanism of action involves restoring gut microbial diversity, strengthening the intestinal barrier, and modulating inflammatory signaling via the LPS/TLR4/NF-κB axis. In oncology, it is studied as an adjunct to immune checkpoint inhibitors, where it appears to enhance therapeutic sensitivity through the cGAS-STING signaling pathway, and as a supportive care agent to reduce chemotherapy-induced myelosuppression and gastrointestinal toxicity.
- Brand names
- Totem Probiotic Fluid
- Other names
- 脆弱拟杆菌BF839Bacteroides fragilis BF839B. fragilis BF839non-enterotoxigenic Bacteroides fragilis BF839
02
Targets
NF-κBTLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on bacteroides fragilis BF839.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacteroides fragilis BF839.